BeOne (ONC) Director Wang Xiaodong Exercises Options, Sells Shares

What Happened

• Wang Xiaodong, a director and Chair of the Scientific Advisory Board at BeOne Medicines (ONC), reported multiple transactions on 2026-09-08. He exercised options to acquire 31,027 shares at $36.90 each (cost ≈ $1,144,896) and executed a series of open‑market sales (reported as disposals) totaling 38,287 ADSs/shares on the same date for aggregate proceeds of about $13,366,092. The filing also reports a disposition of 403,351 derivative securities at $0 (reported as a derivative conversion/settlement).

Key Details

• Transaction date: September 8, 2026; Form 4 filed September 10, 2026 (timely).
• Sales prices (weighted averages and ranges): reported sale prices clustered roughly $344.71–$351.74 per share/ADS (individual weighted‑average prices reported and range footnotes provided).
• Proceeds from sales: ≈ $13.37 million total.
• Option exercise: 31,027 shares at $36.90 ($≈1.145M paid on exercise).
• Derivative item: 403,351 shares reported disposed at $0 (conversion/settlement of derivatives).
• Holdings after transaction: not specified in the provided filing summary.
• Notable footnotes: some sales were made under a Rule 10b5‑1 trading plan (adopted June 9, 2026); each American Depositary Share (ADS) represents 13 ordinary shares; several holdings are held in family trusts or by the reporting person’s spouse, and the reporting person disclaims beneficial ownership of those (see F1–F3). The filing includes weighted‑average price footnotes and an undertaking to provide per‑trade price details on request.
• Exhibit: Power of Attorney listed (Exhibit 24.1).

Context

• The filing shows an exercise at a relatively low strike ($36.90) followed by sales at much higher market prices (~$345–$351). That pattern is commonly seen when insiders exercise and then sell shares (often to cover exercise costs, taxes, or to monetize gains), but the filing itself does not state the insider’s motive.
• The reported 403,351‑share derivative disposition at $0 likely reflects a conversion/settlement of derivative securities; the filing’s footnotes indicate option/derivative terms and vesting schedules apply (see F14–F15).
• These are mostly sales (routine monetization) rather than open‑market purchases; purchases generally carry stronger signals for bullish insider views.